We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

145 hedge funds and large institutions have $322M invested in Cymabay Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

21% more funds holding

Funds holding: 120 → 145 (+25)

14% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 36

23% less capital invested

Capital invested by funds: $416M → $322M (-$94.1M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

52% less call options, than puts

Call options by funds: $1.9M | Put options by funds: $3.98M

Holders
145
Holders Change
+25
Holders Change %
+20.83%
% of All Funds
2.57%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
46
Increased
41
Reduced
36
Closed
21
Calls
$1.9M
Puts
$3.98M
Net Calls
-$2.08M
Net Calls Change
-$4.62M

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$6.59M
2
Goldman Sachs
Goldman Sachs
New York
+$6.44M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$6.11M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.29M
5
BlackRock
BlackRock
New York
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$12.6M
2
RG
Redmile Group
California
-$12.4M
3
VC
Vivo Capital
California
-$11.4M
4
Norges Bank
Norges Bank
Norway
-$7.67M
5
VOYA Investment Management
VOYA Investment Management
Georgia
-$4.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$560K -$68.1K -9,000 -8%
Hudson Bay Capital Management
52
Hudson Bay Capital Management
Connecticut
$532K +$702K +92,759 New
AQR Capital Management
53
AQR Capital Management
Connecticut
$518K +$683K +90,221 New
CAM
54
ClariVest Asset Management
California
$514K -$123K -16,300 -15%
Connor, Clark & Lunn Investment Management (CC&L)
55
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$510K -$723K -95,557 -52%
TCM
56
Tekla Capital Management
Massachusetts
$506K – – –
AP
57
AtonRa Partners
Switzerland
$505K +$666K +87,981 New
UBS AM
58
UBS AM
Illinois
$490K +$647K +85,430 New
JP Morgan Chase
59
JP Morgan Chase
New York
$474K +$430K +56,742 +220%
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$448K +$591K +78,123 New
CSS
61
Cubist Systematic Strategies
Connecticut
$445K +$156K +20,613 +36%
Morgan Stanley
62
Morgan Stanley
New York
$435K +$95.6K +12,635 +20%
Victory Capital Management
63
Victory Capital Management
Texas
$420K +$172K +22,661 +45%
KPF
64
K2 Principal Fund
Ontario, Canada
$412K +$544K +71,862 New
TLP
65
Tri Locum Partners
New York
$356K +$469K +62,000 New
TEE
66
Tibra Equities Europe
United Kingdom
$349K +$460K +60,800 New
JF
67
Jump Financial
Illinois
$348K +$459K +60,690 New
QI
68
QS Investors
New York
$317K +$418K +55,200 New
New York State Common Retirement Fund
69
New York State Common Retirement Fund
New York
$312K – – –
OMC
70
Old Mission Capital
Illinois
$312K +$412K +54,373 New
BAAM
71
Baker Avenue Asset Management
California
$303K -$73.4K -9,700 -16%
TI
72
Trexquant Investment
Connecticut
$302K +$399K +52,695 New
Deutsche Bank
73
Deutsche Bank
Germany
$291K +$21K +2,769 +6%
Citigroup
74
Citigroup
New York
$291K +$259K +34,224 +210%
SO
75
STRS Ohio
Ohio
$289K +$336K +44,400 +740%
1 2
3
4 5

CBAY Hedge Fund Activity: Q4 2020 in Review

145 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2020, worth a combined $322M — down 23% from $416M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new CBAY positions and 21 closed out — a net gain of 25 holders — while 41 added to existing stakes and 36 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $6.59M. The largest seller was Invesco, cutting an estimated $12.6M.

  • 145 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2020, up from 120 in Q3 2020.
  • Funds reported $322M of Cymabay Therapeutics stock for Q4 2020, down 23% quarter-over-quarter.
  • 46 funds opened new Cymabay Therapeutics positions in Q4 2020 and 21 closed out, a net change of +25 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2020 was Two Sigma Investments, an estimated $6.59M added.
  • The largest Cymabay Therapeutics seller in Q4 2020 was Invesco, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2020.